Ugochukwu Nwokoro, MD
Internal Medicine · Dayton, OHNPI 1013919778
Payments from drug & device makers
Across 212 payments — averaging $4598.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$221K
- Genentech, Inc.$191K
- Astrazeneca UK Limited$135K
- Verona Pharma, Inc.$124K
- Bristol Myers Squibb$117K
- Chiesi USA, Inc.$91K
- plus $96K from 28 others
Across 8 payments — averaging $264.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 19 | $221,025 |
| Genentech, Inc. | 35 | $191,014 |
| Astrazeneca UK Limited | 7 | $134,804 |
| Verona Pharma, Inc. | 6 | $123,849 |
| Bristol Myers Squibb | 10 | $117,327 |
| Chiesi USA, Inc. | 18 | $90,931 |
| AstraZeneca | 11 | $65,149 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17,750 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $10,000 |
| Dexcom, Inc. | 16 | $555 |
| Pfizer | 17 | $424 |
| Johnson & Johnson | 14 | $373 |
| Boehringer Ingelheim | 3 | $371 |
| Lilly USA, LLC | 3 | $157 |
| Bayer | 8 | $152 |
| Astellas Pharma US Inc | 5 | $149 |
| Renalytix AI, Inc. | 1 | $124 |
| Abbott | 6 | $122 |
| Novo Nordisk | 4 | $113 |
| Scilex Pharmaceuticals Inc. | 5 | $73 |
| Xeris Pharmaceuticals, Inc. | 3 | $66 |
| BETA Bionics, Inc. | 2 | $63 |
| Exact Sciences | 2 | $47 |
| Grifols USA, LLC | 2 | $38 |
| Corcept Therapeutics | 1 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Valeritas, Inc. | 2 | $30 |
| Novartis | 1 | $25 |
| Radius Health, Inc. | 1 | $23 |
| Insulet Corporation | 1 | $21 |
| AbbVie | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $11 |
How this compares
$974,909 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Dayton
- Richard KimDayton$374K
- Isaac HumphreyDayton$224K
- Amita OzaDayton$195K
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.